Logo
    Search

    #269 - Good vs. bad science: how to read and understand scientific studies

    enSeptember 04, 2023

    Podcast Summary

    • The importance of critical thinking and understanding the research process in comprehending scientific studies.Developing critical thinking skills and understanding the research process allows individuals without scientific backgrounds to accurately interpret and understand scientific studies.

      Understanding scientific studies requires a clear understanding of the research process and critical thinking skills. The process of conducting a study involves formulating a hypothesis, creating a design, and executing the study. Good science is hypothesis-driven and involves testing the null hypothesis, which assumes no relationship between phenomena. It is essential to distinguish between the null and alternative hypothesis to interpret study findings accurately. Additionally, readers must be aware of the limitations and strengths of different types of studies and ask relevant questions to assess their rigor. In today's age of contradictory findings, it is crucial to approach research with skepticism and evaluate the quality of evidence presented in news or publications. Developing these skills will enable individuals with no scientific background to better understand and interpret scientific studies.

    • Steps in Conducting an Experimental StudyConducting an experimental study involves formulating hypotheses, designing the experiment, determining variables, obtaining approvals, defining outcomes, developing a statistical plan, and securing funding.

      Conducting an experimental study involves several important steps. Firstly, formulating a null hypothesis and an alternative hypothesis is crucial. Secondly, designing the experiment, including determining variables such as duration and frequency of coffee consumption and deciding on the measurement of eye color. Additionally, determining the number of subjects and conducting a power analysis are necessary. It is also essential to obtain institutional review board approval if the study involves human or animal subjects. Other steps include defining primary and secondary outcomes, getting protocol approval, developing a statistical plan, and pre-registering the study. Lastly, securing funding is crucial. There are different types of studies, such as observational studies, experimental studies, and summations or analysis of studies.

    • Different Types of Studies in Research and HealthcareDifferent types of studies, from individual case reports to randomized controlled trials, offer valuable insights into medical conditions and treatment options, each contributing to our understanding in their own unique ways.

      Different types of studies serve different purposes in the field of research and healthcare. Individual case reports are valuable for generating hypotheses and highlighting interesting observations, although they may not be generalizable to a larger population. Case series expand on this by examining multiple patients with similar findings and can provide more evidence for hypothesis generation. Cohort studies, whether retrospective or prospective, offer a larger sample size and focus on observing patterns and associations, but do not involve any interventions. Finally, experimental studies, particularly randomized controlled trials, are considered the gold standard for research as they aim to minimize bias by randomly assigning participants to different treatment groups. Each type of study contributes to our understanding of medical conditions and treatment options in their own unique ways.

    • The importance of scrutinizing individual studies within a meta analysisWhile meta analysis can be a powerful tool, it is crucial to evaluate the quality and rigor of the individual studies included in it to determine the reliability of its findings.

      Meta analysis can be a powerful tool in combining data from multiple studies to examine the same question. However, it is important to not blindly trust a meta analysis without scrutinizing each individual study that it includes. The quality and rigor of the constituent studies are crucial in determining the reliability of the meta analysis. Even though meta analysis is often considered the top of the pyramid in terms of evidence, a single well-designed and rigorous randomized controlled trial can still hold more weight and reliability than a poorly constructed meta analysis. Therefore, it is essential to thoroughly evaluate the individual studies within a meta analysis to ensure the validity of its findings. Additionally, the conversation briefly mentions the different phases of clinical trials, with phase 3 trials typically being the final stage before a treatment is approved for use.

    • Phases of drug testing in humansDrug testing in humans involves several phases, starting with safety and tolerability evaluation in phase 1 and progressing to rigorous assessments of both safety and efficacy in phase 3.

      The process of testing new drugs in humans involves several phases, starting with an investigational new drug application (IND) filed with the FDA. Phase 1 focuses on dose escalation and determines the safety and tolerability of the drug in a small group of patients. Phase 2 aims to evaluate safety further and looks for initial signs of efficacy in an open-label fashion. Sometimes, comparisons to the natural history of the disease are made. If the drug successfully passes phase 2, it moves on to phase 3, which is a rigorous trial that thoroughly assesses both safety and efficacy. It is crucial to have both safety and efficacy demonstrated before proceeding to the next phase of testing.

    • The Importance of Large-Scale Clinical Trials in Determining Drug Effectiveness and SafetyRigorous clinical trials are essential for making informed healthcare decisions, as they provide reliable results on the effectiveness and safety of new drugs, unlike observational studies with limitations.

      Conducting large-scale clinical trials, known as phase 3 and post-marketing studies, is crucial to determine the effectiveness and safety of new drugs. These studies involve thousands of patients and often compare standard of care treatment with a new agent. They are conducted in a randomized and blinded manner to ensure reliable results. Phase 4 studies are conducted after drug approval to gather additional information on the drug's efficacy and potential side effects, as well as explore new indications for its use. Observational studies, on the other hand, have limitations due to factors like selection bias and healthy user bias, making it challenging to draw definitive conclusions. Therefore, it is important to rely on rigorous clinical trials to make informed healthcare decisions.

    • Limitations and Flaws of Nutritional EpidemiologyNutritional epidemiology is hindered by recall bias and unreliable data, making it important to approach studies in this field with caution and skepticism.

      Nutritional epidemiology, particularly when it comes to recall bias and food frequency questionnaires, is highly flawed. The reliance on people's ability to accurately recall and report their food consumption over extended periods of time leads to unreliable data. The limitations of this method become even more apparent when compared to the advanced tools and technologies used in other scientific fields. The lack of frequency and specificity in these questionnaires further compounds the problem and hinders the accurate assessment of dietary habits. Therefore, it is crucial to approach studies and findings based on nutritional epidemiology with caution and skepticism, as they may not provide a truly accurate representation of the relationship between diet and health.

    • The limitations of food frequency questionnaires and the influence of observation on behavior in research studies.Food frequency questionnaires may not accurately reflect dietary habits and researchers should consider the potential impact of observation on behavior when designing studies.

      Food frequency questionnaires should be abandoned in research studies. Peter Attia argues that recall is only reliable for profound events like childbirth, not for general dietary habits. Additionally, he questions the validity of inferring causality from recall data due to other factors at play. He criticizes the overemphasis on epidemiology in research, suggesting that its value has been overstated. The conversation also highlights the Hawthorne effect, which states that behavior changes when someone is being observed. This phenomenon can affect study outcomes, particularly in open label trials where competitiveness and performance can be influenced by awareness of observation. Furthermore, the discussion mentions the impact of having someone watch your eating habits, whether physically or virtually. Overall, the accuracy of recall data and the influence of observation on behavior are important considerations in research design.

    • The impact of performance bias and multiple hypothesis testing on clinical trial results.Performance bias and multiple hypothesis testing can lead to misleading results in clinical trials, emphasizing the importance of minimizing these biases for accurate findings.

      Performance bias and multiple hypothesis testing can significantly impact the results of clinical trials. In the example given, the group following the potato diet achieved better weight loss outcomes compared to the calorie restricted group. However, this difference can be attributed to the fact that the potato diet group received more attention, coaching, and positive behavioral influence. Such performance bias can create misleading results in randomized controlled trials, particularly in lifestyle-based studies. Additionally, multiple hypothesis testing can lead to false positives when researchers analyze the data from different angles or conduct multiple tests. It is crucial for researchers to be aware of these biases and design trials that minimize them to ensure accurate and reliable findings.

    • Considerations in Data Analysis: Bonferroni Correction, Confounding Variables, and Randomization in Experimental StudiesWhen analyzing data, remember to apply the Bonferroni correction to account for multiple looks at the data, address confounding variables in observational studies, and ensure rigorous randomization in experimental studies for accurate results.

      When analyzing data, it is important to consider the Bonferroni correction factor to account for multiple looks at the data. This correction factor requires dividing the p value by the number of times the data has been examined, raising the bar for what is considered statistically significant. Additionally, confounding variables, such as age, sex, and smoking, must be addressed in observational studies to mimic the randomization of experiments. However, it is nearly impossible to identify and eliminate all confounders. When evaluating experimental studies, randomization is crucial, and it should be done rigorously to ensure accurate results. A famous example, the Predimed study, was reanalyzed and raised concerns about improper randomization, highlighting the importance of critically examining studies to understand the full story.

    • Understanding the Challenges of Randomized Controlled TrialsProper randomization, differentiation between true randomization and cluster randomization, and careful planning and analysis are essential for accurate and reliable results in randomized controlled trials.

      Designing and conducting randomized controlled trials (RCTs) can be challenging, especially when it comes to the randomization process and control groups. The conversation highlights the importance of differentiating between true randomization and cluster randomization, as well as the need for different statistical adjustments in each case. It also emphasizes the difficulties in implementing a crossover design, where participants serve as their own controls. While this design reduces the number of subjects required and can be cost-effective, it poses challenges in terms of treatment order and potential lingering effects. Ultimately, the discussion underscores the complexity of RCTs and the importance of careful planning and analysis to ensure accurate and reliable results.

    • Factors to Consider in Scientific Studies and Clinical TrialsWhen conducting studies and trials, consider the order of treatments, the importance of blinding, the impact of study population heterogeneity, the clinical significance of outcomes, and potential conflicts of interest.

      When conducting scientific studies and clinical trials, it is crucial to consider several factors. First, the order in which treatments are given can have an impact on the results, with the suggestion being that going from treatment A to B and then from B to A is more effective. Secondly, blinding, whether single or double, is essential to minimize biases and ensure unbiased results. However, blinding can pose challenges, especially in studies involving psychedelics. Furthermore, the study population's heterogeneity affects the generalizability of the findings, and larger studies conducted across multiple sites can bring in more diversity but also introduce potential biases from rogue sites. Additionally, the clinical significance of study outcomes should be taken into account, not just statistical significance. Finally, researchers should be aware of funding sources and potential conflicts of interest that may impact the trial's transparency and reliability.

    • Understanding statistical power and interpreting p values for research findings.Balancing the significance threshold to minimize false positives and false negatives is crucial in statistical analysis, ensuring accurate interpretation of research findings.

      Understanding statistical power and interpreting p values are crucial in interpreting research findings. Power, defined as 1 minus beta, refers to the probability of correctly detecting a true effect or avoiding a false negative. On the other hand, a false positive is represented by the p value (alpha), which indicates the likelihood of observing an effect by chance. It is important to aim for low p values, preferably less than 0.05, to increase confidence in rejecting the null hypothesis. However, setting the p value threshold too low can lead to the risk of discarding relevant information and encountering false negatives. Achieving a balance between minimizing false positives and false negatives is essential in statistical analysis.

    • Understanding Power in Clinical TrialsPower is the ability of a study to detect a true effect. By analyzing a power table, researchers can determine the sample size needed for statistically significant results, avoiding underpowering or overpowered studies. Consider power to ensure valid and relevant findings.

      Understanding power is crucial when designing any kind of clinical trial or experiment. Power refers to the ability of a study to detect a true effect if it exists. It is determined by factors such as the sample size and the expected difference between treatment groups. By analyzing a power table, researchers can determine the number of subjects needed for their study to be statistically significant at a certain level. It is crucial to avoid underpowering a study, where there are not enough participants to detect a true effect, as well as overpowered studies, which may find statistically significant but clinically irrelevant results. By appropriately considering power, researchers can ensure the validity and relevance of their findings.

    • The importance of power in experimental studies and the significance of considering both relative and absolute risk in interpreting study findings.Adequate power in a study is crucial for detecting differences between groups, and understanding both relative and absolute risk is essential for fully understanding the implications of a study.

      Power in experimental studies is crucial and often overlooked. When evaluating a study, it is important to consider if it was adequately powered to detect a difference between the groups being studied. This information is usually found in the study's power analysis or protocol. Understanding the effect size being looked for and the number of participants needed helps determine the reliability of the study's findings. Additionally, researchers often report relative risk without providing absolute risk, which can be misleading. Knowing both the relative and absolute risk is critical in fully understanding the implications of a study. As seen in the example of hormone replacement therapy and breast cancer, the relative risk increase was reported as 25%, but the absolute risk increase was only 1 case per 1000 women, highlighting the importance of considering both measures.

    • Understanding Hazard Ratios and Absolute Risk Reduction in Clinical TrialsUnderstanding hazard ratios and absolute risk reduction is important for analyzing clinical trials and making informed decisions about the effectiveness, side effects, and costs of treatments.

      Understanding hazard ratios and absolute risk reduction is crucial in analyzing clinical trials and making informed decisions. Hazard ratios, calculated using complex math, measure the association between two groups over time. They provide valuable insights into the risk of disease progression or benefits of a treatment. Meanwhile, absolute risk reduction focuses on the actual decrease in events and is essential in determining the number needed to treat (NNT) to achieve a desired outcome. By dividing 1 by the absolute risk reduction, we can determine how many individuals need to receive the treatment to prevent the event. This knowledge is vital as it allows us to evaluate the effectiveness, side effects, and costs of treatments, ensuring informed decision-making.

    • Evaluating Drug Effectiveness: The Number Needed to Treat (NNT) and Confidence IntervalsNNT measures the impact of a drug, with a lower number indicating a more significant effect. Confidence intervals provide insight into study results, helping healthcare professionals make informed treatment decisions.

      The Number Needed to Treat (NNT) is a valuable measure when evaluating the effectiveness of a drug or treatment. A lower NNT indicates a more significant impact. For example, if a drug reduces the risk of death from 4% to 2%, the NNT would be 50, which is impressively low. On the other hand, if the reduction is from 4% to 1%, the NNT would be 33, indicating an even more substantial effect. Additionally, confidence intervals play a crucial role in interpreting study results. A wider interval suggests greater uncertainty, while a narrower interval suggests more confidence in the findings. When the confidence interval includes the value of 1, the results are not considered significant. Understanding NNT and confidence intervals helps healthcare professionals make informed decisions about treatments and interventions.

    • Understanding confidence intervals and the importance of critical thinking in interpreting scientific information.When interpreting studies, consider the confidence intervals to evaluate reliability. Don't rely solely on media for science information; critical thinking and understanding statistical concepts are crucial. Studies may be stopped for various reasons.

      When interpreting studies and scientific information, it is important to understand the concept of confidence intervals and uncertainty. A wider confidence interval indicates greater uncertainty, while a narrower interval indicates more confidence in the results. It is crucial to carefully analyze and consider the confidence intervals presented in studies to evaluate the reliability of the findings. Additionally, when reading scientific papers, it is important to be diligent, pay attention to details, and continuously educate oneself. Science requires critical thinking and the ability to understand statistical concepts. Therefore, relying solely on media or social media platforms for science information may not provide accurate or comprehensive understanding. Finally, studies may be stopped midway due to safety concerns, significant benefits observed, or futility in obtaining meaningful results.

    • Importance of Prioritizing Patient Safety in Clinical TrialsPatient safety should always be the top priority in clinical trials, even if it means stopping the study early.

      Sometimes clinical trials need to be stopped early for safety reasons. This was exemplified by the case of the CTAP inhibitor study, where the trial was set up to compare the combination of the inhibitor with Lipitor to Lipitor alone. The trial intended to follow patients for almost five years, but a monitoring board discovered that a higher number of patients receiving the drug combination had died compared to those on Lipitor alone. This prompted the board to advise Pfizer to halt the trial, which they did. It's important to note that even though the trial was stopped early, a published paper was still produced, reporting the endpoints at the time of study termination. This example demonstrates the significance of prioritizing patient safety in clinical research.

    • Importance of rigorous evaluation and research in pharmaceutical development and drug trials.Thorough research, analysis, and rigorous evaluation are crucial in pharmaceutical development to ensure effectiveness, safety, and credibility of drugs before market release.

      Pharmaceutical companies need to carefully evaluate the effectiveness and safety of their drugs before proceeding with trials and releasing them to the market. The example of CTP inhibitors and the different outcomes observed in previous trials highlight the importance of thorough research and analysis. Even small changes in drug molecules can significantly impact their efficacy and potential side effects. Additionally, the discussion on the Look ahead trial emphasizes the need for futility analysis to determine whether further study is warranted. The process of getting a paper published in a journal also requires rigorous peer review to ensure the quality and credibility of the research. Transparency and consideration of conflicts of interest are vital in this process.

    • Overcoming Publication Bias Through PreregistrationPreregistration of experiments can help mitigate publication bias by ensuring that all studies, regardless of their results, are published, thus promoting unbiased decision-making and advancing scientific knowledge.

      Publication bias poses a significant problem in the scientific community. Many studies, even if they are negative or do not yield the desired results, do not get published. This leads to a lack of comprehensive knowledge and hinders scientific progress. It is crucial to overcome publication bias by implementing strategies such as preregistration. Preregistration requires investigators to register their experiments, including statistical methods, number of subjects, and primary and secondary outcomes, before conducting the study. By making preregistration a prerequisite for publication in scientific journals, it becomes more difficult to selectively publish only positive or favorable results. This helps prevent the distortion of scientific knowledge and supports unbiased decision-making in future research endeavors.

    • The benefits of registered reports in combating publication bias and improving research quality.Registered reports enhance scientific rigor by promoting the publication of negative or neutral results, encouraging peer review of study design, and considering the impact factor when evaluating journal reputation.

      Registered reports are a valuable tool for combating publication bias and ensuring the establishment of knowledge based on rigorous research. With registered reports, researchers submit their protocols for peer review before data collection, and if the protocol is deemed high quality and everything looks good, the study is provisionally accepted for publication. This eliminates the bias towards positive findings and encourages the publication of negative or neutral results that are equally important for the advancement of knowledge. Additionally, registered reports provide an opportunity for peers to identify flaws in study design, such as underpowered experiments, and offer suggestions for improvement. The conversation also highlights the importance of considering the impact factor when evaluating the reputation of journals, with higher impact factors indicating greater citation and recognition within the scientific community.

    • Evaluating the Clinical Significance of Scientific Journals and the Role of OutliersEvaluating scientific papers involves assessing the abstract, study design, results, and discussion sections. Mentorship emphasizes early creation of figures and tables in the research process.

      The impact factor and number of citations of scientific journals can indicate their clinical significance. Journals like the New England Journal of Medicine, Lancet, and JAMA are considered highly influential because of their high impact factors and large number of citations. However, there are outliers like the cancer journal for clinicians, which has a high impact factor despite fewer citations due to its focus on cancer statistics. The process of reading a scientific paper involves first evaluating the abstract to determine interest, then delving into the methods section for details on the study design. Figures and tables in the results section should be stand-alone and easily understandable. Lastly, the discussion section provides additional insights and allows for comparing one's own thoughts with the authors'. Mentorship, as exemplified by Steve Rosenberg's approach, emphasizes the importance of creating figures and tables early in the research process.

    • Mastering Figures and Tables: The Key to Writing a Successful PaperUnderstanding and effectively presenting relevant figures and tables is essential for a successful paper. Providing valuable content and engaging with members through premium benefits helps create a supportive community. Medical advice should be sought from professionals.

      Peter Attia believes that understanding the relevant figures and tables and being able to explain them concisely in a legend is crucial for writing a successful paper. He suggests that once you have this foundation, the rest of the paper comes together easily, with the methods and results sections being straightforward to write. Attia also emphasizes the importance of providing valuable content without relying on paid ads and instead relying on member subscriptions for support. By offering premium membership benefits such as comprehensive show notes, AMA episodes, a premium newsletter, and access to a private podcast feed, he aims to provide members with more value than the cost of the subscription. Additionally, Attia acknowledges that the information shared on his podcast is for informational purposes only and not a substitute for professional medical advice.

    Recent Episodes from The Peter Attia Drive

    #310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.

    #310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Ted Schaeffer is an internationally recognized urologist specializing in prostate cancer and a returning guest on The Drive. In this episode, Ted provides insights into the role testosterone plays, or doesn't play, in the initiation and progression of prostate cancer. He unpacks the findings and limitations of the recent TRAVERSE trial, exploring the complex relationship between testosterone and prostate cancer. Ted delves into the molecular nature of prostate cancer, explaining the androgen receptor saturation theory and the potential impact of testosterone on cancer growth. He also discusses the use of the Decipher test to predict cancer aggressiveness and guide targeted treatment. Furthermore, Ted shares how he counsels patients regarding testosterone replacement therapy (TRT), including its safe administration in patients with low-grade prostate cancer. Additionally, he highlights advancements in prostate cancer therapies and biomarkers that help develop precise treatment strategies while minimizing the need for broad androgen deprivation therapy.

    We discuss:

    • Background on the TRAVERSE trial: insights into exogenous testosterone and prostate cancer risk [3:00];
    • The androgen receptor saturation theory: how different organs respond to varying levels of testosterone [10:30];
    • The relationship between testosterone levels and prostate cancer aggressiveness: how aggressive prostate tumors have lower androgen receptor activity and rely on different growth mechanisms [16:15];
    • Using the Decipher score to assess prostate cancer aggressiveness and guide personalized treatment strategies [23:45];
    • Considerations for testosterone replacement therapy: how Ted counsels patients, how TRT can be safely administered in patients with low-grade prostate cancer, and more [31:15];
    • Advancements in prostate cancer therapies and PSA as a biomarker for precise treatment decisions, minimizing the need for broad androgen deprivation therapy [38:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 22, 2024

    #309 ‒ AI in medicine: its potential to revolutionize disease prediction, diagnosis, and outcomes, causes for concern in medicine and beyond, and more | Isaac Kohane, M.D., Ph.D.

    #309 ‒ AI in medicine: its potential to revolutionize disease prediction, diagnosis, and outcomes, causes for concern in medicine and beyond, and more | Isaac Kohane, M.D., Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Isaac "Zak" Kohane, a pioneering physician-scientist and chair of the Department of Biomedical Informatics at Harvard Medical School, has authored numerous papers and influential books on artificial intelligence (AI), including The AI Revolution in Medicine: GPT-4 and Beyond. In this episode, Zak explores the evolution of AI, from its early iterations to the current third generation, illuminating how it is transforming medicine today and unlocking astonishing possibilities for the future. He shares insights from his unconventional journey and early interactions with GPT-4, highlighting significant AI advancements in image-based medical specialties, early disease diagnosis, and the potential for autonomous robotic surgery. He also delves into the ethical concerns and regulatory challenges of AI, its potential to augment clinicians, and the broader implications of AI achieving human-like creativity and expertise.

    We discuss:

    • Zak’s unconventional journey to becoming a pioneering physician-scientist, and his early interactions with GPT-4 [2:15];
    • The evolution of AI from the earliest versions to today’s neural networks, and the shifting definitions of intelligence over time [8:00];
    • How vast data sets, advanced neural networks, and powerful GPU technology have driven AI from its early limitations to achieving remarkable successes in medicine and other fields [19:00];
    • An AI breakthrough in medicine: the ability to accurately recognize retinopathy [29:00];
    • Third generation AI: how improvements in natural language processing significantly advanced AI capabilities [32:00];
    • AI concerns and regulation: misuse by individuals, military applications, displacement of jobs, and potential existential concerns [37:30];
    • How AI is enhancing image-based medical specialties like radiology [49:15];
    • The use of AI by patients and doctors [55:45];
    • The potential for AI to augment clinicians and address physician shortages [1:02:45];
    • The potential for AI to revolutionize early diagnosis and prediction of diseases: Alzheimer’s disease, CVD, autism, and more [1:08:00];
    • The future of AI in healthcare: integration of patient data, improved diagnostics, and the challenges of data accessibility and regulatory compliance [1:17:00];
    • The future of autonomous robotic surgery [1:25:00];
    • AI and the future of mental health care [1:31:30];
    • How AI may transform and disrupt the medical industry: new business models and potential resistance from established medical institutions [1:34:45];
    • Potential positive and negative impacts of AI outside of medicine over the next decade [1:38:30];
    • The implications of AI achieving a level of creativity and expertise comparable to exceptional human talents [1:42:00];
    • Digital immortality and legacy: the potential to emulate an individual's personality and responses and the ethical questions surrounding it [1:45:45];
    • Parting thoughts [1:50:15]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 15, 2024

    Zone 2 training: impact on longevity and mitochondrial function, how to dose frequency and duration, and more | Iñigo San-Millán, Ph.D. (#201 rebroadcast)

    Zone 2 training: impact on longevity and mitochondrial function, how to dose frequency and duration, and more | Iñigo San-Millán, Ph.D. (#201 rebroadcast)

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Iñigo San-Millán is an internationally renowned applied physiologist and a previous guest on The Drive. His research and clinical work focuses on exercise-related metabolism, metabolic health, diabetes, cancer metabolism, nutrition, sports performance, and critical care. In this episode, Iñigo describes how his work with Tour de France winner Tadej Pogačar has provided insights into the amazing potential of elite athletes from a performance and metabolic perspective. He speaks specifically about lactate levels, fat oxidation, how carbohydrates in food can affect our lactate and how equal lactate outputs between an athlete and a metabolically unhealthy individual can mean different things. Next, he discusses how Zone 2 training boosts mitochondrial function and impacts longevity. He explains the different metrics for assessing one’s Zone 2 threshold and describes the optimal dose, frequency, duration, and type of exercise for Zone 2. Additionally, he offers his thoughts on how to incorporate high intensity training (Zone 5) to optimize health, as well as the potential of metformin and NAD to boost mitochondrial health. Finally, he discusses insights he’s gathered from studying the mitochondria of long COVID patients in the ICU.

    We discuss:

    • The amazing potential of cyclist Tadej Pogačar [2:00];
    • Metrics for assessing athletic performance in cyclists and how that impacts race strategy [7:30];
    • The impact of performance-enhancing drugs and the potential for transparency into athletes’ data during competition [16:15];
    • Tadej Pogačar’s race strategy and mindset at the Tour de France [23:15];
    • Defining Zone 2, fat oxidation, and how they are measured [26:00];
    • Using fat and carbohydrate utilization to calculate the mitochondrial function and metabolic flexibility [35:00];
    • Lactate levels and fat oxidation as it relates to Zone 2 exercise [39:15];
    • How moderately active individuals should train to improve metabolic function and maximize mitochondrial performance [51:00];
    • Bioenergetics of the cell and what is different in elite athletes [56:30];
    • How the level of carbohydrate in the diet and ketogenic diets affects fuel utilization and power output during exercise [1:07:45];
    • Glutamine as a source for making glycogen—insights from studying the altered metabolism of ICU patients [1:14:15];
    • How exercise mobilizes glucose transporters—an important factor in diabetic patients [1:20:15];
    • Metrics for finding Zone 2 threshold—lactate, heart rate, and more [1:24:00];
    • Optimal Zone 2 training: dose, frequency, duration, and type of exercise [1:40:30];
    • How to incorporate high intensity training (Zone 5) to increase VO2 max and optimize fitness [1:50:30];
    • Compounding benefits of Zone 2 exercise and how we can improve metabolic health into old age [2:01:00];
    • The effects of metformin, NAD, and supplements on mitochondrial function [2:04:30];
    • The role of lactate and exercise in cancer [2:12:45];
    • How assessing metabolic parameters in long COVID patients provides insights into this disease [2:18:30];
    • The advantages of using cellular surrogates of metabolism instead of VO2 max for prescribing exercise [2:25:00];
    • Metabolomics reveals how cellular metabolism is altered in sedentary individuals [2:33:00];
    • Cellular changes in the metabolism of people with diabetes and metabolic syndrome [2:38:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 08, 2024

    #308 - AMA #61: Sun exposure, sunscreen, and skin health: relationship between sun exposure and skin cancer, vitamin D production, and photoaging, how to choose a sunscreen, and more

    #308 - AMA #61: Sun exposure, sunscreen, and skin health: relationship between sun exposure and skin cancer, vitamin D production, and photoaging, how to choose a sunscreen, and more

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this “Ask Me Anything” (AMA) episode, Peter delves into two topics that have generated a lot of questions over the years: skin cancer and sunscreen. He begins by exploring the basics of UV radiation, discussing its effects on vitamin D conversion, photoaging, and its role in skin cancer. He examines various skin types, discussing their implications for sun exposure and vitamin D levels, as well as how to determine where you fall on the skin type scale. He then delves into the various types of skin cancer, with a particular emphasis on melanoma, exploring its complex relationship with UV exposure and other contributing risk factors. Additionally, he covers tanning beds, the importance of early skin cancer detection through regular skin checks, and the often confusing topic of sunscreen. He explains how sunscreen affects UV radiation and skin cancer risk, what SPF levels to choose, the differences between organic and mineral sunscreens, and what to consider when selecting the best sunscreen for your needs.

    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #61 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • The impact of UV radiation on the skin [2:00];
    • Understanding solar UV: from the electromagnetic spectrum to skin health [3:45];
    • The role of sunlight in vitamin D production [8:30];
    • Factors contributing to vitamin D deficiency: insufficient UV exposure, magnesium levels, and more [9:45];
    • Sun exposure needs for different skin types, and the limitations of current studies in defining vitamin D deficiency [12:45];
    • The acute and long-term effects of excessive UV exposure: sunburn, photoaging, and the increased risk of skin cancer [15:30];
    • Types of skin cancer and associations with UV exposure [17:45];
    • The complex relationship between melanoma and UV exposure [22:15];
    • Why UV exposure alone doesn’t necessarily explain the risk for melanoma [25:15];
    • Other risk factors for melanoma [29:15];
    • Tanning beds and skin cancer risk [34:45];
    • Balancing sun exposure: benefits and risks [38:15];
    • Tattoos and sun exposure [40:30];
    • The importance of regular skin checks, dermatologists, and emerging technologies showing promise for early detection of cancer [41:45];
    • Self-skin checks: what to look for [46:30];
    • Prevalence of skin cancer and the importance of early detection [49:30];
    • Summary of the major risk factors for melanoma [54:15];
    • The role of sunscreen in reducing skin cancer risk [55:45];
    • How sunscreen works, the differences between chemical and mineral sunscreens, an explanation of SPF, and more [58:30];
    • How to determine the appropriate sunscreen SPF to use based on the UV index [1:04:45];
    • Choosing the right sunscreen for your individual needs [1:07:00];
    • The impact of water and perspiration on sunscreen effectiveness [1:12:00];
    • Chemical vs. mineral sunscreens: safety concerns and recommendations [1:14:00];
    • Concerns about hormone effects from chemical sunscreens [1:19:15];
    • Sunscreen summary: skin types, key considerations, recommended brands, and more [1:23:15]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 01, 2024

    #307 ‒ Exercise for aging people: where to begin, and how to minimize risk while maximizing potential | Peter Attia, M.D.

    #307 ‒ Exercise for aging people: where to begin, and how to minimize risk while maximizing potential | Peter Attia, M.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this special episode, Peter addresses the common questions about starting or returning to an exercise routine over the age of 50. Individuals in this age group have frequently reached out with questions about whether it's too late to start exercising and often express concern over a lack of prior training, a fear of injury, or uncertainty about where to begin. Peter delves into the importance of fitness for older adults, examining all four pillars of exercise, and provides practical advice on how to start exercising safely, minimize injury risk, and maximize potential benefits. Although this conversation focuses on people in the “older” age category, it also applies to anyone of any age who is deconditioned and looking to ease into regular exercise.

    We discuss:

    • Key points about starting exercise as an older adult [2:45];
    • Why it’s never too late to begin exercising and incorporating the four pillars of exercise [5:45];
    • The gradual, then sharp, decline in muscle mass and activity level that occur with age [10:00];
    • The decline of VO2 max that occurs with age [15:30];
    • Starting a training program: exercise variability, movement quality, realistic goals, and more [18:30];
    • Improving aerobic capacity: the malleability of the system, the importance of consistency, and setting long-term fitness goals [25:15];
    • Starting cardio training: base building, starting with low volume, and zone 2 training [30:45];
    • The critical role of VO2 max in longevity [36:45];
    • How to introduce VO2 max training to older or deconditioned individuals [46:15];
    • Options for performing zone 2 and VO2 max training [53:45];
    • The ability to make gains in strength and muscle mass as we age [57:00];
    • How to implement strength training for older individuals [1:01:00];
    • Advice for avoiding injury when strength training [1:07:30];
    • Risk of falls: the devastating consequences and the factors that increase fall risk [1:12:15];
    • Mitigating fall risk: the importance of foot and lower leg strength, ankle mobility, and balance [1:19:45];
    • Improving bone mineral density through resistance training [1:24:30];
    • The importance of protein in stimulating muscle protein synthesis, especially in older adults [1:31:00];
    • Parting advice from Peter [1:34:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJune 24, 2024

    #306 - AMA #60: preventing cognitive decline, nutrition myths, lowering blood glucose, apoB, and blood pressure, and more

    #306 - AMA #60: preventing cognitive decline, nutrition myths, lowering blood glucose, apoB, and blood pressure, and more

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this “Ask Me Anything” (AMA) episode, Peter provides insights on a broad range of important topics. He delves into the prevention of cognitive decline, the link between cardiovascular disease and Alzheimer's disease, and methods to lower blood glucose, insulin, and apoB. He also addresses nutrition-related queries, exploring the impact of dietary habits on weight loss and longevity, how a person can identify the best diet for themselves, and common nutrition myths. Additional discussions include optimal blood pressure, daily step goals, the benefits of standing versus sitting desks, and much more.

    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #60 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • Overview of topics and episode format [1:40];
    • Preventing cognitive decline [5:00];
    • How to lower blood glucose and insulin [13:30];
    • The relationship between lipids, CVD, and Alzheimer’s disease, and whether statins can increase the risk of neurodegenerative disorders and AD [23:15];
    • Reducing apoB levels through exercise and diet [31:45];
    • Pharmacological options for lowering apoB [38:00];
    • How nutrition impacts longevity via metabolic health, muscle mass, BMD and more [40:15];
    • How can someone determine the best diet for themselves? [43:45];
    • Nutrition myth: All weight loss is good [46:45];
    • Nutrition myth: Metabolic rates are dramatically different among individuals based on genetics [49:00];
    • Nutrition myth: Losing weight after a brief period of overeating is impossible [53:45];
    • Nutrition myth: GLP-1 agonists are a replacement for a healthy lifestyle [57:45];
    • Nutrition myth: There is a single best diet for weight loss [1:03:00];
    • Nutrition oversimplification: All calories are created equal [1:05:45];
    • Daily step goals [1:06:45];
    • The benefits of standing versus sitting throughout the day [1:10:45];
    • How to identify the most impactful and easiest-to-implement ways to improve your health [1:12:30];
    • The critical importance of emotional health [1:14:30];
    • Why supplements should be considered as supportive aids rather than primary solutions in one’s strategy to improve longevity [1:18:00];
    • Strategies for reducing high blood pressure [1:20:45];
    • Peter’s biggest frustrations with "mainstream health advice" [1:28:00];
    • Peter’s chaotic, yet cherished, morning routine [1:31:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJune 17, 2024

    #305 ‒ Heart rate variability: how to measure, interpret, and utilize HRV for training and health optimization | Joel Jamieson

    #305 ‒ Heart rate variability: how to measure, interpret, and utilize HRV for training and health optimization | Joel Jamieson

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Joel Jamieson is a conditioning expert who developed Morpheus to give people a smarter way to build their conditioning regimen and improve their recovery. In this episode, Joel dives deep into the world of heart rate variability (HRV), explaining its scientific foundation, how it measures the balance between the sympathetic and parasympathetic nervous systems, the various methods of measurement, and how it can guide healthier lifestyle choices and improved training performance. He explores the nuances of HRV calculation, the impact of aging on HRV, and the roles of genetics, exercise, and other lifestyle factors in this process. He also covers Morpheus, the innovative training tool that won Peter over after his initial skepticism, highlighting its practicality and effectiveness in guiding training and optimizing fitness outcomes.

    We discuss:

    • Heart rate variability (HRV): evolution, science, and practical applications of HRV in athletic training [4:00];
    • Methods of measuring HRV: EKG, wrist-based sensors, and more [11:30];
    • How HRV is calculated from the data [22:30];
    • The role of the autonomic nervous system (ANS) in regulating HRV [25:45];
    • The decline in HRV with age, and the mitigating effects of fitness and other lifestyle factors [33:30];
    • The role of genetics in HRV, the modifiability of HRV, and a comparison of VO2 max and HRV as predictors of mortality [37:00];
    • How aging affects HRV and sympathetic drive, and the importance of spontaneous movement and exercise in maintaining the body's adaptability [43:30];
    • How Morpheus measures HRV using RMSSD and normalizes it to a 100-point scale for easier interpretation [49:45];
    • The Morpheus system: development, integration with various metrics, and personalized daily training recommendations to optimize fitness and recovery [51:30];
    • The benefits of morning HRV readings for assessing daily readiness compared to overnight HRV measurements [1:03:00];
    • Why Morpheus recommends using a chest strap rather than an arm band [1:10:00];
    • The impact of consistent exercise, stress, alcohol, and other lifestyle factors on HRV [1:11:15];
    • Optimizing zone 2 training with Morpheus [1:18:15];
    • Using heart rate recovery (HRR) as an indicator of athletic conditioning and the balance between aerobic and anaerobic systems [1:22:45];
    • The importance of tracking HRV trends over time rather than focusing on data from a given day [1:29:00];
    • Effect of GLP-1 agonists on heart rate and HRV [1:34:45];
    • Where HRV belongs in the hierarchy of health metrics [1:42:00];
    • Parting thoughts [1:46:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJune 10, 2024

    #304 – NEW: Introducing quarterly podcast summaries - Peter shares his biggest takeaways on muscle protein synthesis, VO2 max, toe strength, gut health, and more

    #304 – NEW: Introducing quarterly podcast summaries - Peter shares his biggest takeaways on muscle protein synthesis, VO2 max, toe strength, gut health, and more

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this quarterly podcast summary (QPS) episode, Peter introduces a new format aimed at summarizing his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from each episode, covering diverse topics such as protein and muscle building with Luc van Loon, toe strength with Courtney Conley, VO2 max with Olav Aleksander Bu, liquid biopsies for cancer with Alex Aravanis, gut health and probiotics with Colleen Cutcliffe, and road safety with Mark Rosekind. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these engaging discussions.

    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #304 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • How Peter keeps track of his takeaways from each podcast episode [5:15];
    • Luc van Loon episode: fat utilization, muscle protein synthesis, dietary protein, aging and inactivity, and more [8:45];
    • Behavioral changes that have come about from the conversation with Luc van Loon [23:45];
    • Courtney Conley episode: importance of toe strength and the impact of dedicated foot training [26:45];
    • Olav Aleksander Bu episode: the importance of VO2 max for lifespan, and the practicalities of measuring and improving VO2 max [36:45];
    • Behavioral changes that have come about from the conversation with Olav [56:00];
    • Alex Aravanis episode: liquid biopsies for cancer detection [1:01:30];
    • Colleen Cutcliffe episode: the importance of gut bacteria balance, and the potential therapeutic uses of probiotics, particularly Akkermansia [1:16:45];
    • Mark Rosekind: the significant issue of road fatalities and injuries, their causes, and practical safety measures to reduce risks [1:27:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJune 03, 2024

    #303 - A breakthrough in Alzheimer’s disease: the promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's disease | Dena Dubal, M.D., Ph.D.

    #303 - A breakthrough in Alzheimer’s disease: the promising potential of klotho for brain health, cognitive decline, and as a therapeutic tool for Alzheimer's disease | Dena Dubal, M.D., Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Dena Dubal is a physician-scientist and professor of neurology at UCSF whose work focuses on mechanisms of longevity and brain resilience. In this episode, Dena delves into the intricacies of the longevity factor klotho: its formation and distribution in the body, the factors such as stress and exercise that impact its levels, and its profound impact on cognitive function and overall brain health. Dena shares insights from exciting research in animal models showing the potential of klotho in treating neurodegenerative diseases as well as its broader implications for organ health and disease prevention. She concludes with an optimistic outlook for future research in humans and the potential of klotho for the prevention and treatment of Alzheimer’s disease.

    Disclosure: Peter is an investor in Jocasta Neuroscience, a company working to develop klotho as a therapy for people with Alzheimer’s disease.

    We discuss:

    • Dena’s fascination with aging and how she came to study klotho [3:30];
    • Biological properties of klotho: production, regulation, decline with age, and factors influencing its levels [11:45];
    • Potential benefits of klotho on brain health [22:00];
    • The relationship between soluble klotho protein, platelet factors, and cognitive enhancement [33:45];
    • The role of platelet factor 4 (PF4) and it’s interaction with GluN2B in mediating cognitive enhancement [46:45];
    • Benefits of klotho observed in a mouse model of Parkinson’s disease [55:45];
    • Benefits of klotho observed in a mouse model of Alzheimer’s disease [1:03:00];
    • Promising results of klotho in primate models, and the importance of finding an appropriate therapeutic dose before moving to human trials [1:08:00];
    • Speculating why a single klotho injection has such long-lasting effects [1:25:30];
    • Potential cognitive benefits of klotho in humans, the impact of the KL-VS genetic variant on klotho levels, and the need for human trials to confirm these effects [1:27:45];
    • The interaction between the KL-VS genetic variant and APOE4 and how it impacts risk of Alzheimer’s disease [1:34:45];
    • The significance of klotho levels: studies linking lower levels to increased mortality and the broader implications for organ health and disease prevention [1:47:15];
    • Measuring klotho levels and determining an individual’s KL-VS status [1:52:15];
    • The promising potential of klotho for Alzheimer’s disease treatment, and the importance of philanthropy for funding research [1:58:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enMay 27, 2024

    #302 - Confronting a metabolic epidemic: understanding liver health and how to prevent, diagnose, and manage liver disease | Julia Wattacheril, M.D., M.P.H.

    #302 - Confronting a metabolic epidemic: understanding liver health and how to prevent, diagnose, and manage liver disease | Julia Wattacheril, M.D., M.P.H.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Julia Wattacheril is a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. In this episode, Julia delves deep into the complex world of liver health, beginning with a foundational overview of liver physiology. She provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. She provides a primer on the four major stages of liver disease, discussing risk and emphasizing the importance of early diagnosis. Julia highlights the role of liver disease in increasing the risk of cancer and cardiovascular disease and covers in detail the various strategies for diagnosing, treating, and preventing the progression of liver disease.

    We discuss:

    • Julia’s training, the importance of liver health, and the challenges and innovations of hepatology [3:15];
    • The complex and crucial functionality of the liver, its four most essential functions, and more [8:45];
    • Liver injuries: historical and evolving understanding of causal factors, and the progression to liver diseases and cancer [13:15];
    • How the liver metabolizes nutrients and what happens in the presence of excess calories or alcohol [24:45];
    • Methods of diagnosing liver disease and how insights guide treatment and management strategies [33:30];
    • The poisonous nature of ethanol to the liver [40:30];
    • Varied responses to alcohol, damaging effects of alcohol beyond the liver, and the process of advising patients on their alcohol consumption [47:15];
    • Understanding liver enzymes AST and ALT—interpreting levels, lifestyle factors that affect them, and diagnostic approaches [58:30];
    • Interpreting liver function tests for fatty liver disease, and the challenges of diagnosing liver pathologies, particularly in children versus adults [1:13:15];
    • Comprehensive liver health assessments via imaging and various diagnostic tools to prevent overlooking potential liver pathologies [1:18:45];
    • Potential impact of recreational drugs, statins, and other medications on liver function test results [1:26:45];
    • Shifting nomenclature from NAFLD to MASLD to reflect accuracy in the underlying pathophysiology and understanding of liver diseases [1:30:30];
    • Pathophysiology of MASLD, the need for proactive screening, and the significance of liver fat percentage as an indicator of metabolic health [1:36:30];
    • The importance of screening for rare conditions alongside common metabolic diseases associated with fatty liver accumulation [1:42:45];
    • Practical strategies for managing MAFLD [1:45:30];
    • The impact of fructose consumption on liver health and the challenges of disentangling its effects from other factors like obesity and insulin resistance [1:52:45];
    • The potential of GLP-1 agonists for the treatment of MASLD [1:57:45];
    • How the four stages of liver disease have evolved [2:00:30];
    • Increased cancer and heart disease risk associated with early-stage MAFLD [2:05:15];
    • Emerging drugs and therapies for addressing fat accumulation and fibrosis related to MAFLD [2:12:15];
    • Peter’s major takeaways [2:18:45]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enMay 20, 2024

    Related Episodes

    Ep. 30: The False Choice: Move Fast or Think Deeply

    Ep. 30: The False Choice: Move Fast or Think Deeply

    There is a false dichotomy between thinking deeply and moving fast. We are often presented with these as mutually exclusive choices and both have real advantages. But there is a way to do both at the same time--and it is a life changing insight (at least, it was for me).


    ---


    Sign up to have Scott email you a weekly shot of energy, with 1 Cool Quote, 1 Deep Thought, and 1 Useful Tool. This is original content, not a repost of the podcast. You can find the sign-up section at the bottom of my website www.ScottWozniak.com 


    Learn how Scott and his team of consultants can help you build a legendary brand at www.SwozConsulting.com 


    Connect with Scott on social media:  

    linkedin.com/in/scottwozniak/

    https://www.facebook.com/scottewozniak 


    ------  


    Bonus: check out his other podcast (Alpha Pack): https://kite.link/alpha-pack-podcast 

    If you like this podcast you will probably like that one, too. Who knows, you might even like it better! :)     

    Conducting Clinical Trials Part 1: When Should You File Your Patent Applications?

    Conducting Clinical Trials Part 1: When Should You File Your Patent Applications?
    As the first installment of Choate’s Conducting Clinical Trials series, Bryana McGillycuddy and John Rearick discuss a range of implications associated with the timing of filing, including the validity of the patent and the risk of inadvertent disclosure.

    Pizza, Ot ve Sting: İnternetten Alışverişin Kısa Tarihi

    Pizza, Ot ve Sting: İnternetten Alışverişin Kısa Tarihi

    Selam fularsızlar. Seçim var yarın ama hepimizin kafa kazan gibi olduğu için, söz verdiğim üzere alakasız bir içerikle karşınızdayım: İnternet üzerinden alışveriş tarihinin başlangıcını ve ilginç bazı tekrarlarını göreceğiz, mesela eve teslimat geleneğinin önce yok olup sonra teknolojiyle geri gelmesini göreceğiz. Arada bir Hindistan'a da uğrayıp çıkacağız. Kolay gelsin.


    Konular:

    • (00:20) İnternet üstünden satılan ilk şey.
    • (04:55) Cyber Monday.
    • (06:12) Dabbawala.
    • (10:05) İlk süpermarket.
    • (12:45) Devrimci İngiliz teyze.
    • (16:05) "30 dk veya bedava".
    • (17:30) Zamanının ötesindeki online marketler.
    • (20:38) Pandemi ve alışkanlıkların kırılması.


    Kaynaklar:


    ------- Podbee Sunar -------

    Bu podcast, Samsung hakkında reklam içerir.

    Samsung Galaxy S24/S24+ ve Galaxy S24 Ultra hakkında daha detaylı bilgi için tıklayınız.

    Bu podcast, Salus hakkında reklam içerir.

    Salus hakkında detaylı bilgi almak ve BASLANGIC10 koduyla %10 indirimden faydalanmak için tıklayınız.

    See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

    Launching an NIH Funded Study with Dr. Manish Shah

    Launching an NIH Funded Study with Dr. Manish Shah

    In the fiscal year 2021, the National Institute of Health (NIH) funded only 16,959 out of 80,878 research project grants. 

    In other words, the success rate was 21%.

    And the total funding amount was $8,827,444,624.

    The question I had was, “What does it take to get grant approval and launch an NIH funded research project?”

    To answer this question, I invited Dr. Manish Shah,  Professor of Pediatrics at Baylor College of Medicine and Attending Physician in the Texas Children’s Hospital Emergency Center in Houston. 

    Dr. Shah has served on several national committees to advocate for improvements in pediatric and prehospital emergency care. 

    His research has focused on developing, implementing, and studying outcomes related to evidence-based protocols for various clinical conditions, including seizures. 

    Dr. Shah is currently the Principal Investigator for the Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study, which has been funded by the National Institute of Neurological Disorders and Stroke (NINDS) and is being conducted in the Pediatric Emergency Care Applied Research Network (PECARN).

    Please join me in welcoming Dr. Shah on the Clinical Trial Podcast. 

    This episode is brought you by Florence Healthcare. To learn more, please visit https://florencehc.com/

    Ep. 225 - Outrageous Miscarriage Of Justice In The Smollett Case

    Ep. 225 - Outrageous Miscarriage Of Justice In The Smollett Case

    Today on the Matt Walsh Show, in an outrageous development, Jussie Smollett, who staged a fake hate crime against himself, has been let go. All charges dropped. We will discuss this incredible miscarriage of justice. Also, the president of CNN makes a stunning admission, and a video of Pope Francis that you have to see to believe.  03-26-2019

    Learn more about your ad choices. Visit podcastchoices.com/adchoices